Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (41-50 of 282) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancerSusan Halabi, Eric J Small, Nicholas J Vogelzang
Lifetime Data Analysis|April 14, 2019
Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomesTomoyuki Sugimoto, Toshimitsu Hamasaki, Scott R Evans, et al.
Clinical Trials (London, England)|May 30, 2026
Phase I design for partially ordered groups with late-onset toxicityRami Hawila, Susan Halabi, Ruitao Lin, et al.
Clinical Trials (London, England)|March 30, 2024
Society for Clinical Trials Data Monitoring Committee initiative website: Closing the gapDavid L DeMets, Susan Halabi, Lehana Thabane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2024
Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic LeukemiaAkash Roy, Danielle M Brander, Elizabeth G Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Design issues in randomized phase II/III trialsEdward L Korn, Boris Freidlin, Jeffrey S Abrams, et al.
The American Statistician|September 18, 2009
Flexible Frames and Control Sampling in Case-Control Studies: Weighters (Survey Statisticians) Versus Anti-Weighters (Epidemiologists)Richard F Potthoff, Susan Halabi, Joellen M Schildkraut, et al.
European Urology Open Science|July 26, 2021
In-depth analysis of the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) - The importance of representation of medical specialty and geographic regionsManolis Pratsinis, Susan Halabi, Sabine Güsewell, et al.
Clinical Advances in Hematology & Oncology : H&O|March 19, 2008
Second-line chemotherapy for advanced hormone-refractory prostate cancerEdward G Garmey, Oliver Sartor, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Reply to B. Rini et al and S. Buti et alToni K Choueiri, Susan Halabi, Michael J Morris, et al.
Pageof 29

Showing results (41-50 of 282) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Elevated body mass index predicts for longer overall survival duration in men with metastatic hormone-refractory prostate cancerSusan Halabi, Eric J Small, Nicholas J Vogelzang
Lifetime Data Analysis|April 14, 2019
Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomesTomoyuki Sugimoto, Toshimitsu Hamasaki, Scott R Evans, et al.
Clinical Trials (London, England)|May 30, 2026
Phase I design for partially ordered groups with late-onset toxicityRami Hawila, Susan Halabi, Ruitao Lin, et al.
Clinical Trials (London, England)|March 30, 2024
Society for Clinical Trials Data Monitoring Committee initiative website: Closing the gapDavid L DeMets, Susan Halabi, Lehana Thabane, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2024
Statistical Perspectives and Meta-Analytic Approaches in Surrogate End Point Evaluation for Chronic Lymphocytic LeukemiaAkash Roy, Danielle M Brander, Elizabeth G Hill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Design issues in randomized phase II/III trialsEdward L Korn, Boris Freidlin, Jeffrey S Abrams, et al.
The American Statistician|September 18, 2009
Flexible Frames and Control Sampling in Case-Control Studies: Weighters (Survey Statisticians) Versus Anti-Weighters (Epidemiologists)Richard F Potthoff, Susan Halabi, Joellen M Schildkraut, et al.
European Urology Open Science|July 26, 2021
In-depth analysis of the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) - The importance of representation of medical specialty and geographic regionsManolis Pratsinis, Susan Halabi, Sabine Güsewell, et al.
Clinical Advances in Hematology & Oncology : H&O|March 19, 2008
Second-line chemotherapy for advanced hormone-refractory prostate cancerEdward G Garmey, Oliver Sartor, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 27, 2017
Reply to B. Rini et al and S. Buti et alToni K Choueiri, Susan Halabi, Michael J Morris, et al.
Pageof 29